LRMR250117C10000
- 0.05
- 0.000.00%
Larimar Therapeutics Newsroom
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21
Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $13
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
A Quick Look at Today's Ratings for Larimar Therapeutics(LRMR.US), With a Forecast Between $14 to $36
Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)
Promising Developments and Strategic Regulatory Support Justify Buy Rating for Larimar Therapeutics
Larimar Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Larimar Therapeutics, Maintains $15 Price Target
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $36
Positive Outlook on Larimar Therapeutics' Nomlabofusp for Friedreich's Ataxia: Analyst Recommends Buy Rating
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $21
H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15
Larimar Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
Larimar Therapeutics Analyst Ratings
Citi Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $14
H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $36
Leerink Partners Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26